Condition: Malignancies · Sponsor: Peking University People's Hospital
This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of IASO207 Injection in patients with Relapsed/Refractory B-cell Malignancies。
This description comes directly from the study's public registry record.
Jin Lu, PhD · +86 13311491805 · jin1lu@sina.com
Xuelin Dou，PhD · +86 18514559556 · dxldw@163.com
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07574346